{
  "docId": "019de076-f497-7249-9bc1-6e417e62b814",
  "docSlug": "fb4563ff56b082126dc8200b1dba24d8",
  "documentTitle": "BenevolentAI | Results Presentation Deck | 23 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 23,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 48,
  "notes": "The slide presents a standard financial performance review with a bulleted list of key drivers and a supporting data table.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f497-7249-9bc1-6e417e62b814/15",
  "deckHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814",
  "deckJsonHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814.json",
  "deckAnchorHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.55,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "list",
      "text": "Revenue decreased to £7.3m (2022: £10.6 m) primarily reflecting decreased revenues from the AZ collaboration partly offset by the Merck collaboration. Normalised R&D (excluding SBP), has decreased 13% to £56.5m (2022: £65.1m). This reflects the efforts in the year to optimise its portfolio. Normalised G&A, excluding SBP increased by 36% to £22.4m (2022: £16.5m). Excluding Fx the underlying spend increased by 11% reflecting the additional costs from operating as a public company for a full year. Normalised operating loss decreased by 23% £72.7m (2022: £94.6m). Cash, cash equivalents and short-term deposits position of £72.9m at 31 Dec 2023 (31 Dec 2022: £130.2m), compared with £84.3m at 30 June 2023. Operating cash outflow before changes to working capital of £54.6m (2022: £67.8 m). Post the strategic review cash burn reduced for 2024 and 2025 by around 40% compared to pre-restructuring forecasts and headcount was reduced by c 30%. This led to the cash runway being extended to at least mid-2025 excluding any unsigned revenue or out licensing income",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba2d019f-5310-40fe-b3a8-cc6d3bf00501",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.35,
        "x": 0.6,
        "y": 0.2
      },
      "kind": "table",
      "text": "Financial table showing Revenue, R&D, Admin expenses, Share based payments, Other Income, Operating loss, Finance Income, Finance Expense, Loss before Tax, Taxation, Loss for year, Cash equivalents, and Operating cash outflow for 2023 and 2022.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39c1427f-103f-4a25-ba4a-6ed317e9fb25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "FY 2023 - Financial Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "975f6296-f1fe-420a-988e-6db5fa457354",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 8,
      "beatId": "f2ab71c9-53f6-440d-9d03-02e61c9ddb19",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Discussion of pipeline progression, strategic collaborations, and financial highlights",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 23,
      "from": 1,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "b0e19ace-ba0d-475a-81b8-bb29008de35f",
      "evidence": "The deck's overall narrative and key takeaways",
      "position": 1,
      "objective": "Communicating the why, how, and what of BenevolentAI's AI-driven drug discovery",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}